Du är här


Bavarian Nordic A/S: Bavarian Nordic Announces Activities Around the 2014 ASCO Annual Meeting

KVISTGAARD, Denmark, April 23, 2014
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the company
will be present at the 2014 ASCO Annual Meeting in Chicago, IL from May 30 to
June 3.

Bavarian Nordic will host a PROSTVAC update and reception for members of the
investment community on Saturday, May 31, 2014 in Chicago, IL at 5 PM CDT.

Confirmed speakers and panelists include:

* James L. Gulley, M.D., Ph.D. (NCI)
* Ravi A. Madan, M.D. (NCI)
* Larry Fong, M.D. (University of California San Francisco)
* Winald Gerritsen, M.D., Ph.D. (Radboud University Medical Centre Nijmegen)
* Alex Franzusoff, Ph.D. (SVP R&D, Bavarian Nordic)
* James B. Breitmeyer, M.D., Ph.D. (President, Bavarian Nordic Inc.)

For registration and more information on this event,

Anders Hedegaard, President&CEO of Bavarian Nordic said: "We look forward to
hosting this event which will highlight the potential of the Bavarian Nordic
Cancer Immunotherapy pipeline. We welcome the opportunity to have these key
opinion leaders join members of our management team to discuss the potential
of PROSTVAC in treatment paradigm of men with prostate cancer, both alone and
in combination with other agents."

Bavarian Nordic will also be present at the conference with an exhibit, where
visitors can learn more about PROSTVAC and the PROSPECT clinical trial - a
global, randomized, double-blind, placebo-controlled Phase 3 study of
PROSTVAC® in men with asymptomatic and minimally symptomatic metastatic,
castration-resistant prostate cancer .

Beyond these activities, the company has submitted several scientific
abstracts for presentation at ASCO, and will update the status of these once
the embargo policies permit.

Anders Hedegaard, President&CEO. Phone +45 23 20 30 64

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious
diseases. Lead product candidates are PROSTVAC®, an immunotherapy product
candidate for advanced prostate cancer that is the subject of an ongoing
pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox
vaccine candidate in Phase 3 development, which is being developed and
supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. The vaccine is approved in Canada under
the trade name IMVAMUNE and in the European Union under the trade name

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored
Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visitwww.bavarian-nordic.com.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.